Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Accera logo — Pioneering breakthroughs in neurodegenerative therapies for...

Accera

Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.

Founded 2001 11-50 employees Venture round Total: $196.22M Biotechnology, Health Care +1

General Information

Company Name Accera
Founded Year 2001
Founders / Decision Makers
Team member
Employees 11-50
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Accera. To contact Accera, visit accerapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Accera compare?

A PDF of Accera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Accera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Accera

Accera, established in 2001 and based in Broomfield, Colorado, is a pioneering biotechnology firm in the fields of neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment. The company is focused on the discovery and development of therapeutic drugs aimed at neurodegenerative diseases. Their flagship innovation, Ketasyn, is a molecule intended to address conditions such as Alzheimer's, Parkinson's, and age-related memory impairment. Accera recently received a significant $50.00M in a Venture Round investment on 04 October 2018, with Inventages and Wilmar International as the participating investors. The company’s dedication to addressing critical unmet medical needs in the neurodegenerative space has attracted notable support from leading investors.

Business keywords: neurodegenerative diseases, therapeutic drugs, Alzheimer's, Parkinson's, memory impairment, Ketasyn, drug discovery, drug development

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $50.00M 2
Inventages
Inventages, Wilmar International
04 Oct 2018
Venture Round $17.64M -
26 Mar 2018
Private Equity Round $69.08M -
25 Oct 2013
Series D $11.00M 3
Inventages
Inventages, POSCO BioVentures +1
03 Jan 2011
Series C $35.00M 2
Inventages
Inventages, POSCO BioVentures
12 Nov 2008
Series B $7.50M 1
Inventages
Inventages
16 Aug 2006
Series A $6.00M 1
POSCO BioVentures
16 Sep 2004

Accera Alternatives & Competitors

View All Alternatives
Accera vs
Satori Pharmaceuticals
Satori Pharmaceuticals

Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases.

Venture round
Health Care, Pharmaceutical
Accera vs
Proclara Biosciences
Proclara Biosciences

Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggregation tec...

Venture round
Biotechnology, Health Care
Accera vs
Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. United States

Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.

Grant
13 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Accera

Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.
Accera was founded in 2001.
Accera operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on neurodegenerative diseases, therapeutic drugs, Alzheimer's and Parkinson's.
Accera has approximately 11-50 employees.
Accera has completed 7 funding rounds, raising a total of $196.22M. The latest funding stage is Venture round.
Top alternatives and competitors to Accera include Satori Pharmaceuticals, Proclara Biosciences, Cantabio Pharmaceuticals, Inc., Serenex, ALSP, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Accera and Satori Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Accera, https://bouncewatch.com/company/accera, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout